Revenue
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aquestive Therapeutics, Inc. (AQST)
Price$4.66Cached quote
Net income
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.5M | $57.6M | $50.6M | $47.7M | $50.8M | $45.8M | $52.6M | $67.4M | $66.9M |
| Gross profit | $26.0M | $39.7M | $29.8M | $28.3M | — | $32.9M | $32.2M | — | — |
| Gross margin | 58.35% | 68.95% | 58.82% | 59.34% | — | 71.72% | 61.30% | — | — |
| Research & development | $17.2M | $20.3M | $13.1M | $17.5M | $17.0M | $19.9M | $20.6M | $23.1M | $22.1M |
| Operating expenses | $115.6M | $88.3M | $65.7M | $89.7M | $85.5M | $88.7M | $105.3M | $116.4M | $67.0M |
| Operating income | −$71.1M | −$30.8M | −$15.1M | −$42.1M | −$34.7M | −$42.9M | −$52.7M | −$48.9M | −$113,000 |
| Operating margin | −159.50% | −53.46% | −29.86% | −88.23% | −68.22% | −93.55% | −100.11% | −72.57% | −0.17% |
| EBITDA | −$70.5M | −$30.1M | −$13.8M | −$39.7M | −$31.7M | −$39.5M | −$49.8M | −$45.7M | $3.6M |
| EBITDA margin | −158.27% | −52.21% | −27.20% | −83.22% | −62.39% | −86.04% | −94.59% | −67.85% | 5.44% |
| Net income | −$83.8M | −$44.1M | −$7.9M | −$54.4M | −$70.5M | −$55.8M | −$66.2M | −$61.4M | −$8.9M |
| Net profit margin | −188.09% | −76.68% | −15.56% | −114.11% | −138.77% | −121.67% | −125.92% | −91.02% | −13.36% |
| Basic EPSper basic share | -$0.78 | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 | -$2.61 | -$2.96 | — |
| Diluted EPSper diluted share | -$0.78 | -$0.51 | -$0.13 | -$1.12 | -$1.85 | -$1.66 | -$2.61 | -$2.96 | — |
Owners
Reported shareholders
7.82%of listed shares
Bratton Capital Management, L.P.9.81M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Bratton Capital Management, L.P. | 7.82%9.81M shares |
BlackRock, Inc. | 6.43%8.07M shares |
RTW INVESTMENTS, LP | 5.92%7.43M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.65%4.58M shares |
FEDERATED HERMES, INC. | 2.48%3.11M shares |
STATE STREET CORP | 2.33%2.93M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.09%2.62M shares |
SAMSARA BIOCAPITAL, LLC | 1.99%2.5M shares |
BANK OF AMERICA CORP /DE/ | 1.33%1.67M shares |
Sio Capital Management, LLC | 1.18%1.49M shares |
Propel Bio Management, LLC | 1.15%1.44M shares |
WASATCH ADVISORS LP | 1.10%1.39M shares |
TWO SIGMA INVESTMENTS, LP | 1.02%1.28M shares |
Nuveen, LLC | 0.97%1.22M shares |
Janney Montgomery Scott LLC | 0.88%1.11M shares |
WELLS FARGO & COMPANY/MN | 0.87%1.09M shares |
COMMONWEALTH EQUITY SERVICES, LLC | 0.83%1.05M shares |
BARCLAYS PLC | 0.79%996.67K shares |
Schobel Alexander Mark | ≈0.78%980.73K shares |
Blue Owl Capital Holdings LP | 0.75%942.93K shares |
Percentages use 125.51M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 23, 2026Form 4 · 10b5-1 | Krop JulieDirector | SellCommon Stock | 25.0K | $5.02 | $125.5K | 0 |
| Jun 15, 2026Form 4 · 10b5-1 | Barber DanielPresident and CEO | SellCommon Stock | 25.0K | $4.16 | $104.0K | 635.6K |
| May 15, 2026Form 4 · 10b5-1 | Barber DanielPresident and CEO | SellCommon Stock | 8.3K | $4.29 | $35.4K | 660.6K |
| Mar 10, 2026Form 4 | Boyd Peter E.Chief People Officer | SellCommon Stock | 29.8K | $4.17 | $124.3K | 338.5K |
| Mar 10, 2026Form 4 | Barber DanielPresident and CEO | SellCommon Stock | 180.7K | $4.17 | $753.4K | 1.00M |
Community posts
Aquestive resubmits Anaphylm application after FDA rejection
Aquestive ($AQST) Therapeutics resubmitted its US new-drug application for Anaphylm, a sublingual film containing dibutepinephrine for severe allergic reactions, including anaphylaxis. The submission responds to the FDA’s earlier complete r ...
